Form 4: United Therapeutics EVP Paul Mahon Exercises Share Tracking Awards
SEC Form 4 Filing
Paul Mahon, EVP & General Counsel of United Therapeutics, exercised share tracking awards on February 6, 2025, according to a Form 4 filing.
Summary
- Paul A. Mahon, EVP & General Counsel of United Therapeutics Corporation, executed transactions involving share tracking awards and common stock on February 6, 2025.
- Mahon exercised 7,700 share tracking awards at a price of $163.3.
- The exercised share tracking awards were settled in cash and are non-dilutive stock appreciation rights.
- Mahon also disposed of 7,700 shares of common stock at $353.75.
- Following these transactions, Mahon directly owns 36,710 shares of common stock and 14,250 share tracking awards.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, reflecting routine executive compensation activity. It doesn't inherently convey positive or negative sentiment.
Industry Context
Executive stock transactions are routinely monitored by investors as they can provide insights into an executive's perspective on the company's current valuation and future prospects. The use of 10b5-1 plans is common to avoid accusations of insider trading.
Comparison to Industry Standards
- Executive compensation packages often include stock options, restricted stock units (RSUs), and stock appreciation rights (SARs) like the share tracking awards in this case.
- Companies like Amgen, Biogen, and Gilead Sciences also utilize similar equity-based compensation strategies to align executive interests with shareholder value.
- The specific terms and conditions of these awards, such as vesting schedules and exercise prices, can vary widely based on company performance and industry benchmarks.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it involves the exercise of existing share tracking awards and disposal of a relatively small number of shares.
- The exercise of share tracking awards is cash-settled and non-dilutive, so it does not directly affect the outstanding share count.
Key Dates
| Date | Description |
|---|---|
| 03/13/2016 | Date exercisable for Share Tracking Award |
| 06/20/2024 | Date of pre-arranged 10b5-1 plan entered into by the reporting person |
| 02/06/2025 | Date of transaction (exercise of share tracking awards and disposal of common stock) |
| 03/13/2025 | Expiration date for Share Tracking Award |
| 02/10/2025 | Date of signature for the report |
Keywords
Share Tracking Awards, Form 4, United Therapeutics, UTHR, Paul Mahon, Executive Compensation, Stock Appreciation Rights, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.